AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28626868 — intervention group
Group type: COMPARATOR
Intervention: 2 ml of normal saline (Control)
Number of subjects: 90
Study 24681422 — intervention group
Group type: EXPERIMENTAL
Intervention: Public CLABSI reporting begun by 2006
Number of subjects: 4705857
Study 24681422 — intervention group
Group type: EXPERIMENTAL
Intervention: Public CLABSI reporting begun by 2009
Number of subjects: 4705857
Study 24681422 — intervention group
Group type: COMPARATOR
Intervention: Never reporting states
Number of subjects: 4705857
Study 23746558 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-rich mixed meal (30% of calories from fructose)
Number of subjects: 12
Study 23746558 — intervention group
Group type: COMPARATOR
Intervention: Glucose-rich mixed meal (30% of calories from glucose)
Number of subjects: 12
Study 21242793 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cleaning of the near-patient environment (twice-daily for 2 months)
Number of subjects: 2583
Study 21242793 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cleaning (doctors' hands)
Number of subjects: 2583
Study 21242793 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cleaning (nurses' hands)
Number of subjects: 2583
Study 21242793 — intervention group
Group type: COMPARATOR
Intervention: Standard cleaning
Number of subjects: 2583
Study 18271889 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron 30 mg/day (15 mg twice a day; morning and evening)
Number of subjects: 100
Study 18271889 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice a day)
Number of subjects: 100
Study 17192685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanazole biweekly 1.25 g intravenous infusion 15 minutes before radiotherapy
Number of subjects: 46
Study 17192685 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (control)
Number of subjects: 46
Study 14578723 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted intravenous fluid regimen
Number of subjects: 172
Study 14578723 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous fluid regimen
Number of subjects: 172
Study 11072938 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/day vitamin E
Number of subjects: 196
Study 11072938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 8969353 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (2.5% lidocaine, 2.5% prilocaine) applied 1 hour before phlebotomy
Number of subjects: 0
Study 8969353 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied 1 hour before phlebotomy
Number of subjects: 0
Study 8969353 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 0
Study 1472142 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic powder preparation (900 mg daily for 6 weeks)
Number of subjects: 24
Study 1472142 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study 1472142 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic powder preparation
Number of subjects: 24
Study 6367749 — intervention group
Group type: EXPERIMENTAL
Intervention: goal‐oriented outreach rehabilitation program
Number of subjects: 57
Study 6367749 — intervention group
Group type: COMPARATOR
Intervention: usual treatment
Number of subjects: 57
Study 6367749 — intervention group
Group type: EXPERIMENTAL
Intervention: assistive devices and home modifications
Number of subjects: 57
Study 29575788 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal Peritoneal Dialysis (TPD)
Number of subjects: 125
Study 29575788 — intervention group
Group type: COMPARATOR
Intervention: Continuous Venovenous Hemodiafiltration (CVVHDF)
Number of subjects: 125
Study 26570994 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (omega-3) 3 g/day, taken 3 times a day for 90 days
Number of subjects: 63
Study 26570994 — intervention group
Group type: COMPARATOR
Intervention: Mineral oil (placebo) 3 g/day, taken 3 times a day for 90 days
Number of subjects: 63
Study 24247760 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli strain Nissle 1917 (EcN)
Number of subjects: 0
Study 24247760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23442582 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole-virus HIV vaccine
Number of subjects: 0
Study 23442582 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic HBV vaccine
Number of subjects: 0
Study 23442582 — intervention group
Group type: EXPERIMENTAL
Intervention: New tuberculosis vaccine candidate
Number of subjects: 0
Study 23442582 — intervention group
Group type: EXPERIMENTAL
Intervention: MenB vaccine Bexsero
Number of subjects: 0
Study 23442582 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S malaria vaccine
Number of subjects: 0
Study 19845667 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% niacinamide + 2% NAG in SPF 15 sunscreen moisturizing lotion and evening moisturizing cream (test formulation)
Number of subjects: 202
Study 19845667 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (SPF 15 lotion and cream vehicles)
Number of subjects: 202
Study 19058684 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid etching + Prime & Bond NT
Number of subjects: 192
Study 19058684 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid etching + Single Bond
Number of subjects: 192
Study 19058684 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop
Number of subjects: 192
Study 19058684 — intervention group
Group type: EXPERIMENTAL
Intervention: FL Bond
Number of subjects: 192
Study 19058684 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 192
Study 19058684 — intervention group
Group type: EXPERIMENTAL
Intervention: Mac Bond II
Number of subjects: 192
Study 19058684 — intervention group
Group type: EXPERIMENTAL
Intervention: One Up Bond F
Number of subjects: 192
Study 19058684 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid etching only
Number of subjects: 192
Study 19058684 — intervention group
Group type: EXPERIMENTAL
Intervention: Helioseal F applied alone
Number of subjects: 192
Study 19058684 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch‐and‐rinse adhesives
Number of subjects: 192
Study 16639484 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/weekly + salazopyrin 2 g/daily
Number of subjects: 80
Study 16639484 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/weekly + infliximab 3 mg/Kg at time 0, 2, 4 and every 8 weeks
Number of subjects: 80
Study 16639484 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/weekly + etanercept 25 mg/twice weekly
Number of subjects: 80
Study 16639484 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/weekly + adalimumab 40 mg/every other week
Number of subjects: 80
Study 11834533 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg per day for 4 months)
Number of subjects: 76
Study 9892883 — intervention group
Group type: EXPERIMENTAL
Intervention: Propantheline (15 mg)
Number of subjects: 18
Study 9892883 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 18
Study 7527493 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral surgery
Number of subjects: 556
Study 7527493 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 556
Study 2076384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (0.015 mg/kg intravenously)
Number of subjects: 10
Study 2076384 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (0.1 mg/kg intravenously)
Number of subjects: 10
Study 2076384 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg/day orally)
Number of subjects: 10
Study 2076384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg/day orally)
Number of subjects: 10
Study 2076384 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (intravenous)
Number of subjects: 10
Study 2076384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (intravenous)
Number of subjects: 10
Study 2076384 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (oral)
Number of subjects: 10
Study 2076384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (oral)
Number of subjects: 10
Study 7361794 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal thiopental (25-45 mg/kg)
Number of subjects: 72
Study 7361794 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular cocktail (2.0 mg/kg meperidine, 1.0 mg/kg chlorpromazine, 1.0 mg/kg promethazine)
Number of subjects: 72
Study 31742795 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted sled pushing (light, moderate, heavy resistance)
Number of subjects: 50
Study 31742795 — intervention group
Group type: COMPARATOR
Intervention: Unresisted sled pushing
Number of subjects: 50
Study 31742795 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted sled pushing (heavy load)
Number of subjects: 50
Study 30210103 — intervention group
Group type: EXPERIMENTAL
Intervention: Display group (charges displayed)
Number of subjects: 27
Study 30210103 — intervention group
Group type: COMPARATOR
Intervention: Non-display group (charges not displayed)
Number of subjects: 27
Study 25579006 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior joint space injection of hyaluronic acid (HA)
Number of subjects: 141
Study 25579006 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior joint space injection of hyaluronic acid (HA)
Number of subjects: 141
Study 25579006 — intervention group
Group type: COMPARATOR
Intervention: Comparison between superior and inferior groups
Number of subjects: 141
Study 24952864 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRC treatment
Number of subjects: 27
Study 24952864 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 21956636 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental coated catheter (with athrombogenic Camouflage® layer)
Number of subjects: 179
Study 21956636 — intervention group
Group type: COMPARATOR
Intervention: Standard uncoated catheter
Number of subjects: 179
Study 19164343 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg desloratadine
Number of subjects: 10
Study 19164343 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg montelukast
Number of subjects: 10
Study 19164343 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of desloratadine and montelukast
Number of subjects: 10
Study 19164343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17907854 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for Adolescents with Depression Study (TADS)
Number of subjects: 423
Study 17907854 — intervention group
Group type: EXPERIMENTAL
Intervention: Five classes of symptoms identified through latent profile analysis
Number of subjects: 423
Study 15355145 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus images that reverse or remove the inclusion relationship
Number of subjects: 0
Study 15355145 — intervention group
Group type: EXPERIMENTAL
Intervention: Cat images
Number of subjects: 0
Study 15355145 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog images
Number of subjects: 0
Study 11228580 — intervention group
Group type: EXPERIMENTAL
Intervention: CT venography with caudocranial acquisition starting at 210 seconds
Number of subjects: 50
Study 10216325 — intervention group
Group type: EXPERIMENTAL
Intervention: Template-assisted documentation (T-System)
Number of subjects: 1228
Study 10216325 — intervention group
Group type: COMPARATOR
Intervention: Undirected written documentation
Number of subjects: 1228
Study 8549577 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous contractions (CC) - 30 seconds with 1-minute rest
Number of subjects: 7
Study 8549577 — intervention group
Group type: COMPARATOR
Intervention: Intermittent contractions (IC) - 3 seconds with 2 seconds rest
Number of subjects: 7
Study 2108885 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg leuprorelin acetate depot
Number of subjects: 22
Study 2108885 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg leuprorelin acetate depot
Number of subjects: 22
Study 2108885 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg leuprorelin acetate depot
Number of subjects: 22
Study 2108885 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg, 7.5 mg, and 15 mg leuprorelin acetate depot
Number of subjects: 22
Study 518076 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycosides (n=124)
Number of subjects: 154
Study 518076 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycosides (nephrotoxic patients, n=30)
Number of subjects: 154
Study 518076 — intervention group
Group type: COMPARATOR
Intervention: Control (other antibiotics, n=30)
Number of subjects: 154
Study 30846896 — intervention group
Group type: COMPARATOR
Intervention: Lippes loop intrauterine device (IUD) only
Number of subjects: 72
Study 30846896 — intervention group
Group type: EXPERIMENTAL
Intervention: IUD plus a new crosslinked hyaluronan (NCH) gel
Number of subjects: 72
Study 30846896 — intervention group
Group type: EXPERIMENTAL
Intervention: NCH gel only
Number of subjects: 72
Study 30846896 — intervention group
Group type: COMPARATOR
Intervention: IUD only
Number of subjects: 72
Study 30846896 — intervention group
Group type: EXPERIMENTAL
Intervention: IUD plus NCH
Number of subjects: 72
Study 30846896 — intervention group
Group type: EXPERIMENTAL
Intervention: NCH only
Number of subjects: 72
Study 28159944 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal voice group
Number of subjects: 90
Study 28159944 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 25750038 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute group
Number of subjects: 256
Study 25750038 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute group
Number of subjects: 256
Study 25750038 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute group
Number of subjects: 256
Study 25750038 — intervention group
Group type: COMPARATOR
Intervention: Overall success rates
Number of subjects: 256
Study 25750038 — intervention group
Group type: COMPARATOR
Intervention: Post-ERCP pancreatitis (PEP)
Number of subjects: 256
Study 23916465 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX™ Unicem(®) (3M)
Number of subjects: 16
Study 23916465 — intervention group
Group type: COMPARATOR
Intervention: MIP(®)/Transbond Supreme Low Viscosity(®) (3M)
Number of subjects: 16
Study 21507924 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir hair concentrations
Number of subjects: 424
Study 21507924 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir hair concentrations in subgroups with previous lapses in adherence
Number of subjects: 424
Study 21507924 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir hair concentrations in subgroups with low hair levels
Number of subjects: 424
Study 21507924 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir hair concentrations in subgroups with detectable viremia
Number of subjects: 424
Study 19843321 — intervention group
Group type: EXPERIMENTAL
Intervention: XanGo Juice 18 oz twice daily
Number of subjects: 44
Study 19843321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 19843321 — intervention group
Group type: EXPERIMENTAL
Intervention: XanGo Juice 3 oz twice daily
Number of subjects: 44
Study 19843321 — intervention group
Group type: EXPERIMENTAL
Intervention: XanGo Juice 6 oz twice daily
Number of subjects: 44
Study 17111232 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE-RFA
Number of subjects: 83
Study 17111232 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 83
Study 14644283 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Pringle maneuver
Number of subjects: 40
Study 14644283 — intervention group
Group type: COMPARATOR
Intervention: Inflow plus outflow vascular occlusion
Number of subjects: 40
Study 10874268 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial understanding score
Number of subjects: 20
Study 10874268 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat understanding score
Number of subjects: 20
Study 10874268 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial knowledge of potential benefit
Number of subjects: 20
Study 10874268 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial knowledge of risk
Number of subjects: 20
Study 10874268 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat knowledge of risk
Number of subjects: 20
Study 9032592 — intervention group
Group type: EXPERIMENTAL
Intervention: IPM/CS monotherapy
Number of subjects: 109
Study 9032592 — intervention group
Group type: COMPARATOR
Intervention: IPM/CS combination therapy
Number of subjects: 109
Study 9032592 — intervention group
Group type: COMPARATOR
Intervention: IPM/CS combination therapy with other antibiotics (not penicillins, cephalosporins, or aminoglycosides)
Number of subjects: 109
Study 1523286 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (15 or 20 mg orally)
Number of subjects: 60
Study 1523286 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1.75 or 2.5 mg orally)
Number of subjects: 60
Study 1523286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6498137 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of triamcinolone acetonide
Number of subjects: 69
Study 6498137 — intervention group
Group type: COMPARATOR
Intervention: Conventional incision and curettage
Number of subjects: 69
Study 3946771 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine patch applied to the skin behind one ear
Number of subjects: 42
Study 3946771 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch applied to the skin behind one ear
Number of subjects: 42
Study 3946771 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine patch
Number of subjects: 42
Study 3946771 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 42
Study 31732705 — intervention group
Group type: EXPERIMENTAL
Intervention: PIF8 in far-red light
Number of subjects: 0
Study 31732705 — intervention group
Group type: EXPERIMENTAL
Intervention: PIF8 protein accumulation
Number of subjects: 0
Study 31732705 — intervention group
Group type: COMPARATOR
Intervention: PIF3 protein accumulation
Number of subjects: 0
Study 29620914 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500-850 mg given twice a day)
Number of subjects: 51
Study 29620914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 29620914 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (open-label from week 17 to week 32)
Number of subjects: 51
Study 27140068 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile healthcare application
Number of subjects: 89
Study 27140068 — intervention group
Group type: COMPARATOR
Intervention: Poster
Number of subjects: 89
Study 25325484 — intervention group
Group type: EXPERIMENTAL
Intervention: Home single-channel nasal pressure with manual scoring
Number of subjects: 787
Study 25325484 — intervention group
Group type: EXPERIMENTAL
Intervention: Home single-channel nasal pressure with automatic scoring
Number of subjects: 787
Study 25325484 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 787
Study 22564018 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic load diet
Number of subjects: 80
Study 20865841 — intervention group
Group type: EXPERIMENTAL
Intervention: LGP‐HA + L (Lidocaine hydrochloride 2%)
Number of subjects: 18
Study 20865841 — intervention group
Group type: COMPARATOR
Intervention: LGP‐HA (Control)
Number of subjects: 18
Study 18467288 — intervention group
Group type: EXPERIMENTAL
Intervention: Homecare referral
Number of subjects: 375
Study 18467288 — intervention group
Group type: COMPARATOR
Intervention: No homecare referral
Number of subjects: 375
Study 15671427 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin
Number of subjects: 15570
Study 12656456 — intervention group
Group type: EXPERIMENTAL
Intervention: Toto ointment alone
Number of subjects: 595
Study 12656456 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Toto ointment and soap
Number of subjects: 595
Study 12656456 — intervention group
Group type: COMPARATOR
Intervention: Sulfur ointment alone
Number of subjects: 595
Study 12697510 — intervention group
Group type: EXPERIMENTAL
Intervention: Head down tilt (‐6 degrees HDT)
Number of subjects: 8
Study 12697510 — intervention group
Group type: COMPARATOR
Intervention: Upright control position
Number of subjects: 8
Study 8679235 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine echocardiography alone
Number of subjects: 67
Study 8679235 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine echocardiography with handgrip
Number of subjects: 67
Study 8679235 — intervention group
Group type: COMPARATOR
Intervention: Exercise echocardiography
Number of subjects: 67
Study 8679235 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine echocardiography
Number of subjects: 67
Study 8679235 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine echocardiography with and without handgrip
Number of subjects: 67
Study 1905960 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion A (Intralipid)
Number of subjects: 20
Study 1905960 — intervention group
Group type: COMPARATOR
Intervention: Emulsion B (Tutolipid)
Number of subjects: 20
Study 6132220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed catheters
Number of subjects: 220
Study 6132220 — intervention group
Group type: COMPARATOR
Intervention: Unsealed catheters
Number of subjects: 220
Study 6132220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed catheters among patients receiving systemic antibiotics
Number of subjects: 220
Study 6132220 — intervention group
Group type: COMPARATOR
Intervention: Unsealed catheters among patients receiving systemic antibiotics
Number of subjects: 220
Study 30159604 — intervention group
Group type: EXPERIMENTAL
Intervention: Pennebaker's expressive writing intervention (EWI)
Number of subjects: 71
Study 30159604 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 71
Study 29690736 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic and sedative treatment for 24 hours besides conventional treatment
Number of subjects: 180
Study 29690736 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic and sedative treatment
Number of subjects: 180
Study 29690736 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 180
Study 26890974 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee plus 5 mg.kg anhydrous caffeine (D + C)
Number of subjects: 9